Immunomodulators in infectious diseases: panoply of possibilites

Kn, Masihi

doi:10.1016/s0192-0561(00)00074-6

Cited by 45 publications

(26 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One of the most studied, β-glucan, is derived from the yeast cell walls of Saccharomyces cerevisiae and marketed as Betafectin (Masihi 2000). It affects many in vivo and in vitro activities (Estrada et al 1997).…”

mentioning

confidence: 99%

Down-modulation of lymphoproliferation and interferon-gamma production by beta-glucan derived from Saccharomyces cerevisiae

Pelizon¹,

Kaneno²,

Soares³

et al. 2003

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

mentioning

confidence: 99%

Down-modulation of lymphoproliferation and interferon-gamma production by beta-glucan derived from Saccharomyces cerevisiae

Pelizon¹,

Kaneno²,

Soares³

et al. 2003

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

“…However, some of them have shown side effects that preclude their use in humans. In addition, to achieve optimal results following vaccination, it would be nec- (18). However, only a few muramyl peptides, particularly desmuramyl peptides, have been characterized.…”

Section: Discussionmentioning

confidence: 99%

“…However, the pyrogenic and arthritogenic effects of MDP preclude its use in humans (2). In order to take advantage of its immunomodulatory properties but to minimize the risk of side effects, nontoxic MDP derivatives have been generated, such as the adamantylamide dipeptide (AdDP), MDP-Lys(L18), murabutide (ester derivate), and glucosaminylmuramyl dipeptide (1,18).…”

Section: Muramyl Dipeptide (Mdp; N-acetylmuramyl-l-alanyl-d-iso-mentioning

confidence: 99%

Immune Modulator Adamantylamide Dipeptide Stimulates Efficient Major Histocompatibility Complex Class I-Restricted Responses in Mice

Becker

Nörder

Guzmán

et al. 2007

Clin Vaccine Immunol

View full text Add to dashboard Cite

Adamantylamide L-alanyl-D-isoglutamine (AdDP) is a synthetic adjuvant which belongs to the family of the desmuramyl peptides. AdDP exerts its adjuvant properties when it is administered either by the parenteral or by the mucosal route, leading to the elicitation of strong humoral responses at both the systemic and the mucosal levels. However, very little is known about the effect of AdDP on cellular immunity. Here we demonstrate that AdDP is able to stimulate cellular responses, which are characterized by the release of gamma interferon by CD8؉ T cells when they are restimulated with a major histocompatibility complex class I-restricted peptide and strong in vivo lymphocyte-mediated cytotoxic activity. The capacity of AdDP to stimulate the elicitation of both cellular and humoral adaptive responses makes this adjuvant a promising tool for the development of mucosal vaccine formulations.

show abstract

“…Some of the current immunomodulators comprise microbial products, drugs of natural or synthetic origin, or proteins derived from the immune system [50]. Microbial products like bacterial lysates have already been used to prevent recurrent infection in the lungs.…”

Section: Potential Alternatives To Chemotherapy In Tuberculosis: Immumentioning

confidence: 99%

Cytokines as Immunomodulators in Tuberculosis Therapy

Rivero-Lezcano

2008

PRI

View full text Add to dashboard Cite

The use of cytokines for therapeutic purposes is limited by their high cost and toxicity. Nevertheless, the emergence of extensively drug-resistant tuberculosis (XDR TB), for which chemotherapy is ineffective, has again made cytokine-based therapy attractive as one of the last available options. The results of clinical trials treating pulmonary tuberculosis with cytokines have not been encouraging, making it clear that therapeutic strategies utilizing a single cytokine are inadequate. To develop effective cytokine-based XDR TB therapies, more basic research will be needed to achieve a better understanding of how cytokines promote a successful immune response. We not only have to investigate cytokines already known to participate in tuberculosis, but also the role of other cytokines and chemokines that may enhance both the mycobacterial killing activity of effector cells and the restriction of bacterial intracellular multiplication. There are already several patents involving cytokines for therapeutic use, in the hope of stimulating the immune system in a variety of infectious diseases, including tuberculosis. The validity of these patents needs to be reassessed from a clinical standpoint, and new applications of patents concerning cytokines potentially useful in XDR TB treatment should be encouraged.3

show abstract

Immunomodulators in infectious diseases: panoply of possibilites

Cited by 45 publications

References 69 publications

Down-modulation of lymphoproliferation and interferon-gamma production by beta-glucan derived from Saccharomyces cerevisiae

Down-modulation of lymphoproliferation and interferon-gamma production by beta-glucan derived from Saccharomyces cerevisiae

Immune Modulator Adamantylamide Dipeptide Stimulates Efficient Major Histocompatibility Complex Class I-Restricted Responses in Mice

Cytokines as Immunomodulators in Tuberculosis Therapy

Contact Info

Product

Resources

About